Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Journal of Clinical Oncology - United States
doi 10.1200/jco.2011.35.5040
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Vandetanib Experience in a Patient With Ectopic Cushing Syndrome in Metastatic Medullary Thyroid Cancer

Turkish Journal of Endocrinology and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Duloxetine in Japanese Fibromyalgia Patients

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2015English

Predictive Value of FDG-PET in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2015English

Phase I/Ii Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)

Targeted Oncology
Cancer ResearchOncologyPharmacology
2016English

Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial

The Lancet Oncology
Oncology
2018English

Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial

The Lancet Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy